Here's Why bluebird bio Shares Got Knocked Down 19.3% in December

After Amgen (NASDAQ: AMGN) reported impressive data for its AMG 420 in multiple myeloma at the American Society of Hematology Conference (ASH), shares in bluebird bio (NASDAQ: BLUE) were knocked down 19.3% in December, according to S&P Global Market Intelligence.